BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16163888)

  • 1. [Diabetogenic bladder function diseases. Treatment in open studies with muscarinic receptor antagonists].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):329-30. PubMed ID: 16163888
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of overactive bladder].
    Hunskår S
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2029-30. PubMed ID: 16100546
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of overactive bladder].
    Schiøtz H
    Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2525-6; author reply 2526. PubMed ID: 16186882
    [No Abstract]   [Full Text] [Related]  

  • 4. [Why do physicians prescribe medicine for troublesome urination problems?].
    Lindberg M
    Ugeskr Laeger; 2012 Dec; 174(50):3198; author reply 3198. PubMed ID: 23373074
    [No Abstract]   [Full Text] [Related]  

  • 5. Ability of alpha-lipoic acid to reverse the diabetic cystopathy in a rat model.
    Jiang YJ; Gong DX; Liu HB; Yang CM; Sun ZX; Kong CZ
    Acta Pharmacol Sin; 2008 Jun; 29(6):713-9. PubMed ID: 18501118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bladder storage and voiding dysfunctions : Side effects of drug therapy].
    Wolfesberger J; Falkensammer CE; Madersbacher S
    Urologe A; 2017 Apr; 56(4):456-464. PubMed ID: 28233038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of cyclohexenonic long-chain fatty alcohol to reverse diabetes-induced cystopathy in the rat.
    Saito M; Kinoshita Y; Satoh I; Shinbori C; Suzuki H; Yamada M; Watanabe T; Satoh K
    Eur Urol; 2007 Feb; 51(2):479-87; discussion 487-8. PubMed ID: 16842904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical treatment of voiding problems in men].
    Andersen JT; Nordling J; Walter S
    Ugeskr Laeger; 2007 May; 169(20):1892-4. PubMed ID: 17553364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors involved in the success of antimuscarinic treatment.
    Abrams P; Larsson G; Chapple C; Wein AJ
    BJU Int; 1999 Mar; 83 Suppl 2():42-7. PubMed ID: 10210604
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacological treatment of urinary incontinence.
    Andersson KE; Appell R; Cardozo LD; Chapple C; Drutz HP; Finkbeiner AE; Haab F; Vela Navarrete R
    BJU Int; 1999 Dec; 84(9):923-47. PubMed ID: 10571617
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Schaefer W
    J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326
    [No Abstract]   [Full Text] [Related]  

  • 13. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ability of cyclohexenonic long-chain fatty alcohol to ameliorate diabetes-induced cystopathy in the rat.
    Kazuyama E; Saito M; Okada S; Satoh K
    Pharmacology; 2008; 81(2):137-43. PubMed ID: 17989502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho kinase: a target for treating urinary bladder dysfunction?
    Peters SL; Schmidt M; Michel MC
    Trends Pharmacol Sci; 2006 Sep; 27(9):492-7. PubMed ID: 16870270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of diabetic bladder disorder success fully treated by the injection of steroid hormone into the meningeal cavity of the spine].
    Suzuki H; Ishizuka K; Onai M; Sudo H; Yamada T
    Naika; 1971 May; 27(5):954-6. PubMed ID: 5572496
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
    Mansfield KJ; Chandran JJ; Vaux KJ; Millard RJ; Christopoulos A; Mitchelson FJ; Burcher E
    J Pharmacol Exp Ther; 2009 Mar; 328(3):893-9. PubMed ID: 19029429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Drinka PJ
    J Am Geriatr Soc; 2006 Jun; 54(6):1004-5. PubMed ID: 16776800
    [No Abstract]   [Full Text] [Related]  

  • 19. Fesoterodine (toviaz) for overactive bladder.
    Med Lett Drugs Ther; 2009 May; 51(1311):34-5. PubMed ID: 19417719
    [No Abstract]   [Full Text] [Related]  

  • 20. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.